Secondary Logo

Institutional members access full text with Ovid®

Mandibular Regeneration With Autologous Human Bone Marrow Derived Mesenchymal Stem Cells to Treat Unicystic Ameloblastoma

A Clinical Report

Son, Jeong Wan, DDS, MSD*; Kim, Bong Chul, DDS, PhD*; Yoon, Jung Hoon, DDS, PhD; Jun Lee, , DDS, PhD*,‡; Lim, Hun Jun, DDS, PhD*

Journal of Craniofacial Surgery: May 2019 - Volume 30 - Issue 3 - p e187–e189
doi: 10.1097/SCS.0000000000004917
Brief Clinical Studies
Buy

Ameloblastoma is a rare, benign tumor found in the jaw. These tumors have a tendency for locally aggressive expansion, and thus require surgical removal. For the previous 3 decades, autologous bone grafting and free flap surgeries have been most commonly used to correct bone defects after surgical removal of the lesion. In this report, the authors describe a case of unicystic ameloblastoma in a 14-year-old girl who was successfully treated with mandibular regeneration, attained by autologous human bone marrow mesenchymal stem cells without any autologous bone graft and free flap transfer. This case shows that autologous human bone marrow mesenchymal stem cells can be used as an alternative method to autologous bone graft and free flap transfer in a large bone defect of the jaw.

*Department of Oral and Maxillofacial Surgery

Department of Oral and Maxillofacial Pathology

Wonkwang Bone Regeneration Research Institute, Daejeon Dental Hospital, College of Dentistry, Wonkwang University, Daejeon, Republic of Korea.

Address correspondence and reprint requests to Hun Jun Lim, DDS, PhD, Assistant Professor, Department of Oral and Maxillofacial Surgery, Daejeon, Dental Hospital, College of Dentistry, Wonkwang University, 77 Dunsan-ro, Seo-gu, Daejeon 35233, Republic of Korea; E-mail: hun216@gmail.com

Received 3 April, 2018

Accepted 10 July, 2018

This work was supported by Wonkwang University in 2017.

This study was approved by the local ethics committee of the Daejeon Dental Hospital, College of Dentistry, Wonkwang University, Daejeon, Korea, after obtaining written consent from the patient (IRB No. W1720/001-001).

The authors report no conflicts of interest.

© 2019 by Mutaz B. Habal, MD.